Forskning ved Københavns Universitet - Københavns Universitet

Forside

Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. / Miller, Anne-Marie; Balasa, Mircea; Blennow, Kaj; Gardiner, Mary; Rutkowska, Aleksandra; Scheltens, Philip; Teunissen, Charlotte E; Visser, Pieter Jelle; Winblad, Bengt; Waldemar, Gunhild; Lawlor, Brian.

I: Journal of Alzheimer's Disease, Bind 60, Nr. 1, 2017, s. 201-210.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Miller, A-M, Balasa, M, Blennow, K, Gardiner, M, Rutkowska, A, Scheltens, P, Teunissen, CE, Visser, PJ, Winblad, B, Waldemar, G & Lawlor, B 2017, 'Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe', Journal of Alzheimer's Disease, bind 60, nr. 1, s. 201-210. https://doi.org/10.3233/JAD-170502

APA

Miller, A-M., Balasa, M., Blennow, K., Gardiner, M., Rutkowska, A., Scheltens, P., Teunissen, C. E., Visser, P. J., Winblad, B., Waldemar, G., & Lawlor, B. (2017). Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease, 60(1), 201-210. https://doi.org/10.3233/JAD-170502

Vancouver

Miller A-M, Balasa M, Blennow K, Gardiner M, Rutkowska A, Scheltens P o.a. Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease. 2017;60(1):201-210. https://doi.org/10.3233/JAD-170502

Author

Miller, Anne-Marie ; Balasa, Mircea ; Blennow, Kaj ; Gardiner, Mary ; Rutkowska, Aleksandra ; Scheltens, Philip ; Teunissen, Charlotte E ; Visser, Pieter Jelle ; Winblad, Bengt ; Waldemar, Gunhild ; Lawlor, Brian. / Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. I: Journal of Alzheimer's Disease. 2017 ; Bind 60, Nr. 1. s. 201-210.

Bibtex

@article{b4fbfc17c5f945bead56505a62c32fd8,
title = "Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe",
abstract = "BACKGROUND: BIOMARKAPD seeks to diminish the barriers associated with the clinical use of cerebrospinal fluid (CSF) biomarker analysis by reducing variation in CSF laboratory methodologies and generating consensus recommendations on their clinical interpretation and application for dementia diagnosis.OBJECTIVE: To examine the disparity in practitioner attitudes and clinical practice relating to the use of CSF biomarkers for dementia diagnosis across Europe.METHODS: Clinical dementia experts were surveyed on the prevalence of national consensus guidelines and analytical reimbursement across Europe, their biomarker platform preferences, lumbar puncture methodologies and application of reference values and cut-offs for CSF analysis.RESULTS: 74% of respondents (total n = 51) use CSF biomarkers in clinical practice and 69% perform lumbar punctures on an outpatient basis. Most use CSF biomarkers to diagnose atypical (84%) and early-onset cases of cognitive impairment (71%) and for the differential diagnosis of other dementias (69%). 82% state they are sufficiently informed about CSF biomarkers yet 61% report a lack of national consensus guidelines on their use for dementia diagnosis. 48% of countries represented do not reimburse clinical CSF analysis costs. 43% report using normal reference ranges derived from publications.CONCLUSION: Variations in attitude and practice relating to CSF biomarkers, widely recognised as barriers to their clinical acceptance, remain evident within and between countries across Europe, even in expert centres. These shortcomings must be addressed by developing consensus guidelines on CSF-related methodologies and their clinical application, to further their use for the diagnostic evaluation of dementia.",
keywords = "Journal Article",
author = "Anne-Marie Miller and Mircea Balasa and Kaj Blennow and Mary Gardiner and Aleksandra Rutkowska and Philip Scheltens and Teunissen, {Charlotte E} and Visser, {Pieter Jelle} and Bengt Winblad and Gunhild Waldemar and Brian Lawlor",
year = "2017",
doi = "10.3233/JAD-170502",
language = "English",
volume = "60",
pages = "201--210",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "I O S Press",
number = "1",

}

RIS

TY - JOUR

T1 - Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe

AU - Miller, Anne-Marie

AU - Balasa, Mircea

AU - Blennow, Kaj

AU - Gardiner, Mary

AU - Rutkowska, Aleksandra

AU - Scheltens, Philip

AU - Teunissen, Charlotte E

AU - Visser, Pieter Jelle

AU - Winblad, Bengt

AU - Waldemar, Gunhild

AU - Lawlor, Brian

PY - 2017

Y1 - 2017

N2 - BACKGROUND: BIOMARKAPD seeks to diminish the barriers associated with the clinical use of cerebrospinal fluid (CSF) biomarker analysis by reducing variation in CSF laboratory methodologies and generating consensus recommendations on their clinical interpretation and application for dementia diagnosis.OBJECTIVE: To examine the disparity in practitioner attitudes and clinical practice relating to the use of CSF biomarkers for dementia diagnosis across Europe.METHODS: Clinical dementia experts were surveyed on the prevalence of national consensus guidelines and analytical reimbursement across Europe, their biomarker platform preferences, lumbar puncture methodologies and application of reference values and cut-offs for CSF analysis.RESULTS: 74% of respondents (total n = 51) use CSF biomarkers in clinical practice and 69% perform lumbar punctures on an outpatient basis. Most use CSF biomarkers to diagnose atypical (84%) and early-onset cases of cognitive impairment (71%) and for the differential diagnosis of other dementias (69%). 82% state they are sufficiently informed about CSF biomarkers yet 61% report a lack of national consensus guidelines on their use for dementia diagnosis. 48% of countries represented do not reimburse clinical CSF analysis costs. 43% report using normal reference ranges derived from publications.CONCLUSION: Variations in attitude and practice relating to CSF biomarkers, widely recognised as barriers to their clinical acceptance, remain evident within and between countries across Europe, even in expert centres. These shortcomings must be addressed by developing consensus guidelines on CSF-related methodologies and their clinical application, to further their use for the diagnostic evaluation of dementia.

AB - BACKGROUND: BIOMARKAPD seeks to diminish the barriers associated with the clinical use of cerebrospinal fluid (CSF) biomarker analysis by reducing variation in CSF laboratory methodologies and generating consensus recommendations on their clinical interpretation and application for dementia diagnosis.OBJECTIVE: To examine the disparity in practitioner attitudes and clinical practice relating to the use of CSF biomarkers for dementia diagnosis across Europe.METHODS: Clinical dementia experts were surveyed on the prevalence of national consensus guidelines and analytical reimbursement across Europe, their biomarker platform preferences, lumbar puncture methodologies and application of reference values and cut-offs for CSF analysis.RESULTS: 74% of respondents (total n = 51) use CSF biomarkers in clinical practice and 69% perform lumbar punctures on an outpatient basis. Most use CSF biomarkers to diagnose atypical (84%) and early-onset cases of cognitive impairment (71%) and for the differential diagnosis of other dementias (69%). 82% state they are sufficiently informed about CSF biomarkers yet 61% report a lack of national consensus guidelines on their use for dementia diagnosis. 48% of countries represented do not reimburse clinical CSF analysis costs. 43% report using normal reference ranges derived from publications.CONCLUSION: Variations in attitude and practice relating to CSF biomarkers, widely recognised as barriers to their clinical acceptance, remain evident within and between countries across Europe, even in expert centres. These shortcomings must be addressed by developing consensus guidelines on CSF-related methodologies and their clinical application, to further their use for the diagnostic evaluation of dementia.

KW - Journal Article

U2 - 10.3233/JAD-170502

DO - 10.3233/JAD-170502

M3 - Journal article

C2 - 28826189

VL - 60

SP - 201

EP - 210

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -

ID: 185365119